Summary
Fifty-five patients with antibodies to HCV and chronic liver disease have been enrolled in the study. Thirty-four patients were treated with recombinant alpha interferon (IFN, 3 MU daily for 10 days followed by 3 MU twice/week for 3 months), and were compared to 21 untreated controls.
Alanine aminotransferase (ALT) normalization was observed in a significant proportion of treated patients (52.9%), but 66.6% of them experienced a relapse after discontinuation of the therapy. The evaluation of the early ALT behavior after the 10 days priming with daily IFN administration was useful in predicting the response.
The administration of a second IFN course with the same schedule and duration as the first course did not increase the efficacy of the treatment. Increased dosage and/or prolonged administration are probably required.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Di Bisceglie AM, Martin P, Kassianides C et al (1989) Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 321: 1506–1510
Davis GL, Baiart LA, Schiff ER et al (1989) Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial. N Engl J Med 321: 1501–1506
Saracco G, Rosina F, Torrani Cerenzia MR et al (1990) A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. J Hepatol 11 [Suppl]: 43–49
Ferenci P, Vogel W, Pristautz H et al (1990) One-year treatment of chronic non-A, non-B hepatitis with interferon alfa 2b. J Hepatol 11 [Suppl]: 50–53
Jacyna MR, Brooks MG, Loke RHT et al (1989) Randomized controlled trial of interferon alpha (lymphoblastoid interferon) in chronic non-A, non-B hepatitis. Br Med J 298: 80–82
Hoofnagle JH, Mullen KD, Jones DB et al (1986) Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. N Engl J Med 315: 1575–1578
Gomez-Rubio M, Porres JC, Castillo I et al (1990) Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group. J Hepatol 11 [Suppl]: 63–67
Taliani G, Lecce R, Clementi C, Furlan C, De Bac C (1991) Antibodies to hepatitis C virus and response to Interferon treatment in non-A, non-B chronic hepatitis. J Hepatol 12: 264–265
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag
About this paper
Cite this paper
Taliani, G. et al. (1992). One course versus two courses of recombinant alpha interferon in chronic C hepatitis. In: De Bac, C., Taliani, G., Gerlich, W.H. (eds) Chronically Evolving Viral Hepatitis. Archives of Virology, vol 4. Springer, Vienna. https://doi.org/10.1007/978-3-7091-5633-9_66
Download citation
DOI: https://doi.org/10.1007/978-3-7091-5633-9_66
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82350-7
Online ISBN: 978-3-7091-5633-9
eBook Packages: Springer Book Archive